MedPath

Research for biomarkers to predict the effectiveness of zoledronic acid in metastatic bone tumors

Not Applicable
Conditions
Patients with bone metastases newly treated by zoledronic acid
Registration Number
JPRN-UMIN000018556
Lead Sponsor
agoya University Graduate School and School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
27
Inclusion Criteria

Not provided

Exclusion Criteria

Fracture, No consent, Contraindication for zoledronic acid

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Therapeutic effects of CT and bone scintigraphy (3 and 6 months after treatments)
Secondary Outcome Measures
NameTimeMethod
Value and change of biomarkers, Pain score, Analgesic score, Side effect, PS
© Copyright 2025. All Rights Reserved by MedPath